SLN vs. TYRA, RLAY, RGNX, ZVRA, UPB, AMLX, ARVN, DNA, ALT, and SAGE
Should you be buying Silence Therapeutics stock or one of its competitors? The main competitors of Silence Therapeutics include Tyra Biosciences (TYRA), Relay Therapeutics (RLAY), REGENXBIO (RGNX), Zevra Therapeutics (ZVRA), Upstream Bio (UPB), Amylyx Pharmaceuticals (AMLX), Arvinas (ARVN), Ginkgo Bioworks (DNA), Altimmune (ALT), and Sage Therapeutics (SAGE). These companies are all part of the "pharmaceutical products" industry.
Silence Therapeutics vs.
Tyra Biosciences (NASDAQ:TYRA) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, community ranking, dividends, risk, institutional ownership, profitability and valuation.
Silence Therapeutics has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.
Tyra Biosciences has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Comparatively, Silence Therapeutics has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.
Tyra Biosciences has a net margin of 0.00% compared to Silence Therapeutics' net margin of -342.00%. Tyra Biosciences' return on equity of -24.56% beat Silence Therapeutics' return on equity.
In the previous week, Tyra Biosciences had 8 more articles in the media than Silence Therapeutics. MarketBeat recorded 10 mentions for Tyra Biosciences and 2 mentions for Silence Therapeutics. Tyra Biosciences' average media sentiment score of 1.32 beat Silence Therapeutics' score of 1.25 indicating that Tyra Biosciences is being referred to more favorably in the media.
Tyra Biosciences currently has a consensus price target of $30.83, suggesting a potential upside of 215.92%. Silence Therapeutics has a consensus price target of $33.83, suggesting a potential upside of 558.24%. Given Silence Therapeutics' higher possible upside, analysts plainly believe Silence Therapeutics is more favorable than Tyra Biosciences.
Silence Therapeutics received 8 more outperform votes than Tyra Biosciences when rated by MarketBeat users. Likewise, 78.95% of users gave Silence Therapeutics an outperform vote while only 77.08% of users gave Tyra Biosciences an outperform vote.
84.1% of Tyra Biosciences shares are owned by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are owned by institutional investors. 15.4% of Tyra Biosciences shares are owned by insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Silence Therapeutics beats Tyra Biosciences on 9 of the 16 factors compared between the two stocks.
Get Silence Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Silence Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SLN) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy SLN Stock Free SLN Stock Alerts